Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Cozzolongo

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Immunopharmacology and Immunotoxicology|April 17, 1998
Soluble (s) CD14 and plasmatic lipopolysaccharides (LPS) in patients with chronic hepatitis C before and after treatment with interferon (IFN)-alphaE Jirillo, L Amati, L Caradonna, et al.
Current Pharmaceutical Design|April 12, 2002
Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-alpha/ribavirinL Amati, L Caradonna, T Magrone, et al.
Gastroenterology|June 26, 1999
Changing pattern of chronic hepatitis D in Southern EuropeF Rosina, P Conoscitore, R Cuppone, et al.
Alimentary Pharmacology & Therapeutics|March 13, 2010
Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirinA Mangia, O Dalgard, N Minerva, et al.
Current Pharmaceutical Design|April 12, 2002
Biological and clinical significance of endotoxemia in the course of hepatitis C virus infectionL Caradonna, M L Mastronardi, T Magrone, et al.
Journal of Viral Hepatitis|September 3, 2008
Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirinA Andriulli, C Cursaro, R Cozzolongo, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 24, 2011
Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-αC Scagnolari, S Trombetti, A Soldà, et al.
Acta Gastro-Enterologica Belgica|December 29, 2021
Worldwide prevalence, genotype distribution and management of hepatitis CP Guntipalli, R Pakala, S Kumari Gara, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Immunopharmacology and Immunotoxicology|April 17, 1998
Soluble (s) CD14 and plasmatic lipopolysaccharides (LPS) in patients with chronic hepatitis C before and after treatment with interferon (IFN)-alphaE Jirillo, L Amati, L Caradonna, et al.
Current Pharmaceutical Design|April 12, 2002
Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-alpha/ribavirinL Amati, L Caradonna, T Magrone, et al.
Gastroenterology|June 26, 1999
Changing pattern of chronic hepatitis D in Southern EuropeF Rosina, P Conoscitore, R Cuppone, et al.
Alimentary Pharmacology & Therapeutics|March 13, 2010
Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirinA Mangia, O Dalgard, N Minerva, et al.
Current Pharmaceutical Design|April 12, 2002
Biological and clinical significance of endotoxemia in the course of hepatitis C virus infectionL Caradonna, M L Mastronardi, T Magrone, et al.
Journal of Viral Hepatitis|September 3, 2008
Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirinA Andriulli, C Cursaro, R Cozzolongo, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 24, 2011
Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-αC Scagnolari, S Trombetti, A Soldà, et al.
Acta Gastro-Enterologica Belgica|December 29, 2021
Worldwide prevalence, genotype distribution and management of hepatitis CP Guntipalli, R Pakala, S Kumari Gara, et al.
Pageof 2